Browsing by Author "Naggie, Susanna"
Now showing items 1-20 of 31
-
A cross-sectional analysis of HIV and hepatitis C clinical trials 2007 to 2010: the relationship between industry sponsorship and randomized study design.
(Trials, 2014-01)<h4>Background</h4>The proportion of clinical research sponsored by industry will likely continue to expand as federal funds for academic research decreases, particularly in the fields of HIV/AIDS and hepatitis C (HCV). ... -
A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial.
(The lancet. Gastroenterology & hepatology, 2022-04)<h4>Background</h4>Despite widespread availability of direct-acting antivirals including generic formulations, limited progress has been made in the global adoption of hepatitis C virus (HCV) treatment. Barriers to treatment ... -
A randomized, double-blind, placebo-controlled clinical trial of fluconazole as early empiric treatment of coccidioidomycosis pneumonia (Valley Fever) in adults presenting with community-acquired pneumonia in endemic areas (FLEET-Valley Fever).
(Contemp Clin Trials Commun, 2021-12)Introduction: Coccidioidomycosis is a fungal infection endemic in the southwestern United States (US). Primary pulmonary coccidioidomycosis (PPC) is a leading cause of community-acquired pneumonia (CAP) in this region, although ... -
An integrated alcohol abuse and medical treatment model for patients with hepatitis C.
(Dig Dis Sci, 2012-04)BACKGROUND: Patients with chronic hepatitis C virus (HCV) infection have high rates of alcohol consumption, which is associated with progression of fibrosis and lower response rates to HCV treatment. AIMS: This prospective ... -
Antiretroviral Effects on Host Lipoproteins Are Associated With Changes in Hepatitis C Virus (HCV) RNA Levels in Human Immunodeficiency Virus/HCV Coinfected Individuals.
(Open forum infectious diseases, 2015-04)We evaluated the impact of antiretroviral-induced dyslipidemia on hepatitis C virus (HCV) biogenesis in human immunodeficiency virus (HIV)/HCV coinfected patients. This study used serum samples from antiretroviral-naive ... -
Author Correction: Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials.
(Nature communications, 2021-05-14)The original version of this Article contained an error in the spelling of the author Muhammad Shahzad, which was incorrectly given as Muhammad Shehzad. This has now been corrected in both the PDF and HTML versions of the ... -
Cardiovascular Disease Risk Management in Persons With HIV: Does Clinician Specialty Matter?
(Open forum infectious diseases, 2020-09)<h4>Background</h4>The impact of clinician specialty on cardiovascular disease risk factor outcomes among persons with HIV (PWH) is unclear.<h4>Methods</h4>PWH receiving care at 3 Southeastern US academic HIV clinics between ... -
Community-based HCV screening: knowledge and attitudes in a high risk urban population.
(BMC Infect Dis, 2014-02-10)BACKGROUND: In an attempt to curtail the rising morbidity and mortality from undiagnosed HCV (hepatitis C virus) in the United States, screening guidelines have been expanded to high-risk individuals and persons born 1945-1965. ... -
Correlation Between Tenofovir Drug Levels and the Renal Biomarkers RBP-4 and ß2M in the ION-4 Study Cohort.
(Open forum infectious diseases, 2019-01)<h4>Background</h4>Concomitant dosing of ledipasvir (LDV) and tenofovir disoproxil fumarate (TDF) results in an increased tenofovir (TFV) area under the curve (AUC). The aim of this study was to examine whether there was ... -
COVID-19 Trials: Who Participates and Who Benefits?
(Southern medical journal, 2022-04)<h4>Objectives</h4>The coronavirus disease 2019 (COVID-19) pandemic has disproportionately afflicted vulnerable populations. Older adults, particularly residents of nursing facilities, represent a small percentage of the ... -
COVID-19-Lessons Learned and Questions Remaining.
(Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021-06)In this article, the editors of Clinical Infectious Diseases review some of the most important lessons they have learned about the epidemiology, clinical features, diagnosis, treatment and prevention of SARS-CoV-2 infection ... -
Cumulative Human Immunodeficiency Virus (HIV)-1 Viremia Is Associated With Increased Risk of Multimorbidity Among US Women With HIV, 1997-2019.
(Open forum infectious diseases, 2023-02)<h4>Background</h4>To evaluate the effect of cumulative human immunodeficiency virus (HIV)-1 viremia on aging-related multimorbidity among women with HIV (WWH), we analyzed data collected prospectively among women who achieved ... -
Design of the Healthcare Worker Exposure Response and Outcomes (HERO) research platform.
(Contemporary clinical trials, 2021-10)<h4>Background</h4>The SARS CoV-2 virus has caused one of the deadliest pandemics in recent history, resulting in over 170 million deaths and global economic disruption. There remains an urgent need for clinical trials to ... -
Developing Treatment Guidelines During a Pandemic Health Crisis: Lessons Learned From COVID-19.
(Annals of internal medicine, 2021-08)The development of the National Institutes of Health (NIH) COVID-19 Treatment Guidelines began in March 2020 in response to a request from the White House Coronavirus Task Force. Within 4 days of the request, the NIH COVID-19 ... -
Development and evaluation of a novel training program to build study staff skills in equitable and inclusive engagement, recruitment, and retention of clinical research participants.
(Journal of clinical and translational science, 2022-01)<h4>Background</h4>Adequate equitable recruitment of underrepresented groups in clinical research and trials is a national problem and remains a daunting challenge to translating research discoveries into effective healthcare ... -
Direct-Acting Antivirals Improve Access to Care and Cure for Patients With HIV and Chronic HCV Infection.
(Open Forum Infect Dis, 2018-01)Background: Direct-acting antivirals (DAA) as curative therapy for hepatitis C virus (HCV) infection offer >95% sustained virologic response (SVR), including in patients with human immunodeficiency virus (HIV) infection. ... -
Feasibility and willingness-to-pay for integrated community-based tuberculosis testing.
(BMC Infect Dis, 2011-11-02)BACKGROUND: Community-based screening for TB, combined with HIV and syphilis testing, faces a number of barriers. One significant barrier is the value that target communities place on such screening. METHODS: Integrated ... -
Geographic information system-based screening for TB, HIV, and syphilis (GIS-THIS): a cross-sectional study.
(PLoS One, 2012)OBJECTIVE: To determine the feasibility and case detection rate of a geographic information systems (GIS)-based integrated community screening strategy for tuberculosis, syphilis, and human immunodeficiency virus (HIV). ... -
Increased Glutaminolysis Marks Active Scarring in Nonalcoholic Steatohepatitis Progression.
(Cellular and molecular gastroenterology and hepatology, 2020-01)<h4>Background & aims</h4>Nonalcoholic steatohepatitis (NASH) occurs in the context of aberrant metabolism. Glutaminolysis is required for metabolic reprograming of hepatic stellate cells (HSCs) and liver fibrogenesis in ... -
Lower likelihood of cardiac procedures after acute coronary syndrome in patients with human immunodeficiency virus/acquired immunodeficiency syndrome.
(Medicine, 2018-02)Cardiovascular disease (CVD) is an increasing cause of morbidity and mortality in human immunodeficiency virus (HIV)-infected adults; however, this population may be less likely to receive interventions during hospitalization ...
